A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder
Eligible age
18+ yrs
Accepts
All genders
Locations
12 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a global, phase 3, randomized, double-blind, parallel-group, 3-arm, placebo-controlled, multicenter study designed to compare the efficacy, safety, and tolerability of fixed doses of SEP-363856 (50 and 75 milligrams per day \[mg/day\]) to placebo in adults at least 18 years of age with generalized anxiety disorder (GAD) over 8 weeks.
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Where it's recruiting
Tucson
Encino · Sherman Oaks
Washington D.C.
Gainesville · Jacksonville · Maitland
Warrenville
New Orleans
Boston
Las Vegas
New York
Independence
Oklahoma City
Dallas · DeSoto
Source: ClinicalTrials.gov · NCT07759128 · last updated 2026-10-26